Skip to Content

Preparation H Rapid Relief with Lidocaine Cream (glycerin / lidocaine / petrolatum / phenylephrine topical) Disease Interactions

There are 8 disease interactions with Preparation H Rapid Relief with Lidocaine Cream (glycerin / lidocaine / petrolatum / phenylephrine topical):

Major

Lidocaine (applies to Preparation H Rapid Relief with Lidocaine Cream) teething pain

Major Potential Hazard, Moderate plausibility. Applicable conditions: Teething Syndrome

Topical lidocaine is not recommended to be used in teething infants and young children, as its ingestion is dangerous and potentially fatal. Ingestion of the drug has shown to result in seizures, severe brain injury, and heart problems in children.

Major

Lidocaine topical (applies to Preparation H Rapid Relief with Lidocaine Cream) cardiovascular dysfunction

Major Potential Hazard, Moderate plausibility. Applicable conditions: Heart Block, Shock

Lidocaine is absorbed through intact skin and mucosal membranes following topical administration. Prolonged exposure, large doses, frequent applications and/or use on compromised skin or mucosa can produce systemic effects. At high plasma levels, lidocaine can cause hypotension, bradycardia, and cardiovascular collapse. Therapy with lidocaine topical should be administered cautiously in patients with shock, sinus bradyarrhythmia, or severe heart block. The recommended dosage should not be exceeded. Children and debilitated, elderly, or acutely ill patients should be given reduced dosages commensurate with their age, weight, and physical condition.

Major

Lidocaine topical (applies to Preparation H Rapid Relief with Lidocaine Cream) hepatic dysfunction

Major Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease

Lidocaine topical is absorbed through intact skin and mucosal membranes. Prolonged exposure, large doses, and/or application to compromised skin or mucosa can result in elevated plasma concentrations of lidocaine. Lidocaine is rapidly and extensively metabolized by the liver. Less than 10% is eliminated unchanged in the urine. Several inactive and two active forms (MEGX and GX) have been identified. MEGX and GX exhibit antiarrhythmic and convulsant properties. The pharmacokinetic disposition of lidocaine is altered by changes in hepatic function, including hepatic blood flow. Therapy with lidocaine topical should be administered cautiously and dosing modified for patients with compromised hepatic function.

Major

Lidocaine topical (applies to Preparation H Rapid Relief with Lidocaine Cream) renal dysfunction

Major Potential Hazard, Moderate plausibility.

Lidocaine topical is absorbed through intact skin and mucosal membranes. Prolonged exposure, large doses, and/or application to compromised skin or mucosa can result in elevated plasma concentrations of lidocaine. Lidocaine is primarily eliminated by the kidney. Less than 10% is eliminated unchanged in the urine. Two active metabolites (MEGX and GX) have been identified that exhibit antiarrhythmic and convulsant properties. Serum concentrations of lidocaine and the active metabolites are increased and the half-life prolonged in patients with renal impairment. Therapy with lidocaine topical should be administered cautiously and dosing modified for repeated doses in patients with compromised renal function.

Major

Lidocaine topical (applies to Preparation H Rapid Relief with Lidocaine Cream) seizures

Major Potential Hazard, Moderate plausibility.

Lidocaine topical is absorbed through intact skin and mucosal membranes. Prolonged exposure, large doses, and/or application to compromised skin or mucosa can result in elevated plasma concentrations of lidocaine. Seizures can occur as a result of accumulation of active metabolites. Therapy with lidocaine topical should be administered cautiously to patients with or predisposed to seizure disorders.

Moderate

Topical phenylephrine (applies to Preparation H Rapid Relief with Lidocaine Cream) cardiovascular

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Cardiovascular Disease, Cerebrovascular Insufficiency, Hyperthyroidism

Topically applied sympathomimetic agents are systemically absorbed, with the potential for producing clinically significant systemic effects, particularly during prolonged or indiscriminate use. In cardiac tissues, these agents may produce positive chronotropic and inotropic effects via stimulation of beta-1 adrenergic receptors. Cardiac output, oxygen consumption, and the work of the heart may be increased. In the peripheral vasculature, vasoconstriction may occur via stimulation of alpha-1 adrenergic receptors. The use of topical sympathomimetic agents has rarely been associated with palpitations, tachycardia, arrhythmia, hypertension, reflex bradycardia, and coronary occlusion. Therapy with topical sympathomimetic agents should be administered cautiously in patients with sensitivity to sympathomimetic amines, hyperthyroidism, or underlying cardiovascular or cerebrovascular disorders, especially coronary insufficiency, cardiac arrhythmia, or hypertension.

References

  1. "Product Information. Neo-Synephrine Nasal (phenylephrine nasal)" Southwood Pharmaceuticals Inc, Irvine, CA.
  2. Lansche RK "Systemic reactions to topical epinephrine and phenylephrine." Am J Ophthalmol 61 (1966): 95-8
  3. Ellis PP "Systemic reactions to topical therapy." Int Ophthalmol Clin 11 (1971): 1-11
  4. "Product Information. Neo-Synephrine (phenylephrine ophthalmic)" Sanofi Winthrop Pharmaceuticals, New York, NY.
View all 4 references
Moderate

Topical sympathomimetics (applies to Preparation H Rapid Relief with Lidocaine Cream) BPH

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Benign Prostatic Hyperplasia, Prostate Tumor

Topically applied sympathomimetic agents are systemically absorbed, with the potential for producing clinically significant systemic effects, particularly during prolonged or indiscriminate use. In patients with prostate enlargement, urinary difficulty may develop or worsen due to smooth muscle contraction in the bladder neck via stimulation of alpha-1 adrenergic receptors. Therapy with topical sympathomimetic agents should be administered cautiously in patients with hypertrophy or neoplasm of the prostate. It is important that the recommended dosages of the individual products not be exceeded.

References

  1. "Product Information. Collyrium Fresh (tetrahydrozoline)." Wyeth-Ayerst Laboratories, Philadelphia, PA.
  2. "Product Information. Naphcon (naphazoline ophthalmic)" Alcon Laboratories Inc, Fort Worth, TX.
  3. "Product Information. Afrin (oxymetazoline nasal)" Schering-Plough, Liberty Corner, NJ.
  4. "Product Information. Neo-Synephrine Nasal (phenylephrine nasal)" Southwood Pharmaceuticals Inc, Irvine, CA.
  5. "Product Information. Pretz-D (ephedrine nasal)" Parnell Pharmaceuticals Inc, San Rafael, CA.
  6. "Product Information. Benzedrex (propylhexedrine nasal)" Menley and James Laboratories Inc, Horsham, PA.
  7. "Product Information. Neo-Synephrine (phenylephrine ophthalmic)" Sanofi Winthrop Pharmaceuticals, New York, NY.
  8. "Product Information. Otriviv (xylometazoline nasal)" Novartis Pharmaceuticals, East Hanover, NJ.
  9. "Product Information. Ocuclear (oxymetazoline ophthalmic)" Schering-Plough, Liberty Corner, NJ.
  10. Ellis PP "Systemic reactions to topical therapy." Int Ophthalmol Clin 11 (1971): 1-11
  11. "Product Information. Tyzine (tetrahydrozoline)." Kenwood Laboratories, Fairfield, NJ.
  12. "Product Information. Vicks Vapor Inhaler (desoxyephedrine nasal)" Procter and Gamble Pharmaceuticals, Cincinnati, OH.
  13. "Product Information. Privine (naphazoline nasal)" Novartis Consumer Health, Summit, NJ.
  14. Lansche RK "Systemic reactions to topical epinephrine and phenylephrine." Am J Ophthalmol 61 (1966): 95-8
View all 14 references
Moderate

Topical sympathomimetics (applies to Preparation H Rapid Relief with Lidocaine Cream) diabetes

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Diabetes Mellitus

Topically applied sympathomimetic agents are systemically absorbed, particularly during prolonged or indiscriminate use. Slight increases in blood glucose concentrations may occur with the use of these drugs. Therapy with topical sympathomimetic agents should be administered cautiously in patients with diabetes mellitus. Closer monitoring of blood glucose concentrations may be appropriate. It is important that the recommended dosages of the individual products not be exceeded.

References

  1. "Product Information. Ocuclear (oxymetazoline ophthalmic)" Schering-Plough, Liberty Corner, NJ.
  2. "Product Information. Vicks Vapor Inhaler (desoxyephedrine nasal)" Procter and Gamble Pharmaceuticals, Cincinnati, OH.
  3. "Product Information. Otriviv (xylometazoline nasal)" Novartis Pharmaceuticals, East Hanover, NJ.
  4. Lansche RK "Systemic reactions to topical epinephrine and phenylephrine." Am J Ophthalmol 61 (1966): 95-8
  5. Ellis PP "Systemic reactions to topical therapy." Int Ophthalmol Clin 11 (1971): 1-11
  6. "Product Information. Privine (naphazoline nasal)" Novartis Consumer Health, Summit, NJ.
  7. "Product Information. Neo-Synephrine (phenylephrine ophthalmic)" Sanofi Winthrop Pharmaceuticals, New York, NY.
  8. "Product Information. Collyrium Fresh (tetrahydrozoline)." Wyeth-Ayerst Laboratories, Philadelphia, PA.
  9. "Product Information. Benzedrex (propylhexedrine nasal)" Menley and James Laboratories Inc, Horsham, PA.
  10. "Product Information. Naphcon (naphazoline ophthalmic)" Alcon Laboratories Inc, Fort Worth, TX.
  11. "Product Information. Tyzine (tetrahydrozoline)." Kenwood Laboratories, Fairfield, NJ.
  12. "Product Information. Afrin (oxymetazoline nasal)" Schering-Plough, Liberty Corner, NJ.
  13. "Product Information. Neo-Synephrine Nasal (phenylephrine nasal)" Southwood Pharmaceuticals Inc, Irvine, CA.
  14. "Product Information. Pretz-D (ephedrine nasal)" Parnell Pharmaceuticals Inc, San Rafael, CA.
View all 14 references

Preparation H Rapid Relief with Lidocaine Cream (glycerin / lidocaine / petrolatum / phenylephrine topical) drug interactions

There are 83 drug interactions with Preparation H Rapid Relief with Lidocaine Cream (glycerin / lidocaine / petrolatum / phenylephrine topical)

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.